# ULTRATRACE Iobenguane I 131 in Patients With Malignant Pheochromocytoma, Paraganglioma, or Metastatic Carcinoid

> **NCT00339131** · PHASE1 · COMPLETED · sponsor: **Molecular Insight Pharmaceuticals, Inc.** · enrollment: 24 (estimated)

## Conditions studied

- Pheochromocytoma
- Paraganglioma
- Carcinoid

## Interventions

- **DRUG:** Ultratrace iobenguane I 131

## Key facts

- **NCT ID:** NCT00339131
- **Lead sponsor:** Molecular Insight Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-06
- **Primary completion:** —
- **Final completion:** 2007-01
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2011-10-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00339131

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00339131, "ULTRATRACE Iobenguane I 131 in Patients With Malignant Pheochromocytoma, Paraganglioma, or Metastatic Carcinoid". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00339131. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*